Reviva Pharmaceuticals Holdings, Inc. Investing Cash Flow
Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported Investing Cash Flow of $26.36 million for the 9-month period ending 2020-11-30, per its 10-Q filed 2021-01-14.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2021-01-14
- Reviva Pharmaceuticals Holdings, Inc. net cash provided by (used in) investing activities for the quarter ending 2020-11-30 was -$206.12K.
- Reviva Pharmaceuticals Holdings, Inc. net cash provided by (used in) investing activities for the quarter ending 2020-08-31 was -$210.84K.
- Reviva Pharmaceuticals Holdings, Inc. net cash provided by (used in) investing activities for the quarter ending 2020-05-31 was $26.77M.
- Reviva Pharmaceuticals Holdings, Inc. net cash provided by (used in) investing activities for the quarter ending 2020-02-29 was $5.70M.
- Reviva Pharmaceuticals Holdings, Inc. net cash provided by (used in) investing activities for fiscal 2020 was $5.70M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 5 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 8 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 11 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|---|---|---|
| 2020-11-30 | -$206.12K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-01-14 | -$416.96K derived: sum of 2 quarters · filed 2021-01-14 | $26.36M 10-Q · filed 2021-01-14 | $32.06M derived: sum of 4 quarters · filed 2021-01-14 | |||
| 2020-08-31 | -$210.84K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-10-14 | $26.56M 10-Q · filed 2020-10-14 | $32.26M derived: sum of 3 quarters · filed 2020-10-14 | $32.26M derived: sum of 4 quarters · filed 2021-01-14 | |||
| 2020-05-31 | $26.77M 10-Q · filed 2020-07-07 | $32.47M derived: sum of 2 quarters · filed 2020-07-07 | $32.47M derived: sum of 3 quarters · filed 2021-01-14 | $32.47M derived: sum of 4 quarters · filed 2021-01-14 | |||
| 2020-02-29 | $5.70M derived: 10-K 12 month − 10-Q 9 month · filed 2020-05-04 | $5.70M derived: sum of 2 quarters · filed 2021-01-14 | $5.70M derived: sum of 3 quarters · filed 2021-01-14 | $5.70M 10-K · filed 2020-05-04 | |||
| 2019-11-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-01-14 | $0.00 derived: sum of 2 quarters · filed 2021-01-14 | $0.00 10-Q · filed 2021-01-14 | ||||
| 2019-08-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-10-14 | $0.00 10-Q · filed 2020-10-14 | |||||
| 2019-05-31 | $0.00 10-Q · filed 2020-07-07 | ||||||
| 2019-02-28 | -$64.52M 10-K · filed 2020-05-04 | ||||||
| 2018-11-30 | -$64.52M 10-Q · filed 2020-01-10 | ||||||
| 2018-08-31 | -$64.52M 10-Q · filed 2019-10-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |